XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 33.53

-2.8%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nowandthen who wrote (17113)	12/15/2004 1:29:36 AM
From: zax	Read Replies (1) of 17367

There were fatalities due to fatal sepsis in the follow-up to the Raptiva general trial. There are no immunosuppressants, especially tumor necrosis factor inhibitors, that are perfectly safe. It would be very naive for anyone to think so. Raptiva has become quite generally known to be bad news amongst the membership of the National Psoriasis Foundation. The horror stories are abundant. Psoriatic arthritis is far worse ailment then psoriasis. Since many members have developed PA 3 to 4 months after starting Raptiva, as well as severe gutate, and commonly discontinuing Raptiva will cause 80% gutate body coverage, I can understand this. So, XOMA my have other drugs that are quite good, and I make no analysis about whatever other drugs they have in the field or in their pipeline for other medical conditions. And I make no statement as to what their stock may be worth. I'm only saying that Raptiva drug doesn't appear to be a good or safe therapy for psoriasis. And thats just my two cents, for what its worth.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next